Conversion of centrally authorized products into national UK Marketing authorisations in case of No Deal Brexit

Graphic design Logo

4 December 2018

BlueReg

MHRA has sent to Marketing Authorization Holder (MAH) a guidance outlining requirements for submitting baseline information on your product in case of Brexit No Deal Scenario .

As MAH, you should be prepared, and BlueReg can provide regulatory and publishing support whatever the scenario for Brexit (“Deal or No Deal”) .

“In the unlikely event that the UK leaves the EU in a no deal scenario, the UK will need to put in place arrangements for the continued authorisation of medicinal products. This letter is to inform you of the actions we intend to take concerning CAPs and the actions we need you to take as a Marketing Authorisation Holder (MAH) of a CAP in the event of a ‘no deal’ scenario [..].”

Read more :

UK CAP conversion 1st info 26-11-18 MHRA CAP Conversion - eSubmission Requirements Guidance Document

UK CAP conversion 1st info 26-11-18 MHRA CAP conversion Letter

BlueReg

Did you like this article? Share on social networks:

Associated News

BlueReg continues to expand in the US opening its second North American office in Boston

Cambridge, Massachusetts, USA, December 13 2019, BlueReg, the consulting organization for life sciences companies, is...

Download now

The French system for preventing and managing shortages

The French regulation on the prevention and management of stock shortages of medicinal products is...

Download now

FDA GUIDANCE – COVID-19

BlueReg continues to monitor the changes in the regulatory guidance and we wish to share...

Download now